A guest column published by BioStock argues that life sciences have become intertwined with geopolitics, with the United States tightening industrial policy and China strengthening its role as an innovation driver [1].
The column states that Chinese companies have increased their influence in global innovation chains, including clinical development and international licensing, and claims China assumed leadership in new pharmaceutical substances two years ago [1].
Europe is described as positioned between these developments and at risk of reacting to external decisions rather than shaping its own trajectory in research, investment, and production [1].
For Sweden, the piece emphasizes the need to enhance attractiveness through faster patient access to medicines, effective regulatory processes, and predictability for company investments [1].
The Swedish election campaign is presented as an opportunity to discuss life science's role in national competitiveness, though the column reflects one industry association perspective and requires independent verification per available assessments [1].